Fycompa

Pre-clinicalCompleted
0 watching 0 views this week๐Ÿ’ค Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Partial Seizures (With or Without Secondary Generalized Seizures)

Conditions

Partial Seizures (With or Without Secondary Generalized Seizures), Primary Generalized Tonic-clonic Seizures

Trial Timeline

Aug 1, 2016 โ†’ Sep 13, 2019

About Fycompa

Fycompa is a pre-clinical stage product being developed by Eisai for Partial Seizures (With or Without Secondary Generalized Seizures). The current trial status is completed. This product is registered under clinical trial identifier NCT03059329. Target conditions include Partial Seizures (With or Without Secondary Generalized Seizures), Primary Generalized Tonic-clonic Seizures.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (3)

NCT IDPhaseStatus
NCT03208660Pre-clinicalCompleted
NCT03059381Pre-clinicalCompleted
NCT03059329Pre-clinicalCompleted

Competing Products

20 competing products in Partial Seizures (With or Without Secondary Generalized Seizures)

See all competitors
ProductCompanyStageHype Score
E2007EisaiPhase 3
77
PerampanelEisaiPre-clinical
23
perampanel + perampanelEisaiPhase 1
33
perampanel + perampanel + perampanel + PlaceboEisaiPhase 3
77
Perampanel + PlaceboEisaiApproved
85
Perampanel and Microgynon-30 + Perampanel and Microgynon-30EisaiPhase 1
33
perampanelEisaiPhase 2
52
PerampanelEisaiPre-clinical
23
Zonisamide + PlaceboEisaiPhase 3
77
zonisamideEisaiPre-clinical
23
E2007 (perampanel) + E2007 (perampanel) + PlaceboEisaiPhase 3
77
Perampanel + PlaceboEisaiPhase 3
77
E2007 (perampanel) + E2007 (perampanel) + PlaceboEisaiPhase 3
77
Adjunctive Zonisamide + Replacement with ZonisamideEisaiApproved
85
FycompaEisaiPre-clinical
23
Zonisamide + PlaceboEisaiPhase 3
77
RufinamideEisaiPhase 3
77
ZonisamideEisaiPhase 3
77
Eslicarbazepine Acetate tabletsEisaiPre-clinical
23
PerampanelEisaiPre-clinical
23